Overview

Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee

Status:
Completed

Trial end date:
2020-12-18

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate the effect of fasinumab compared to placebo on peripheral nerves in participants with pain due to Osteoarthritis (OA) of the hip or knee. The secondary objectives of the study are to: - Evaluate the efficacy of fasinumab compared to placebo in participants with pain due to OA of the hip or knee - Evaluate the safety and tolerability of fasinumab compared to placebo in participants with pain due to OA of the hip or knee - Characterize the concentrations of fasinumab in serum in participants with pain due to OA of the hip or knee - Evaluate the immunogenicity of fasinumab in participants with pain due to OA of the hip or knee.

Phase:

Phase 2

Details

Lead Sponsor:

Regeneron Pharmaceuticals

Collaborator:

Teva Pharmaceutical Industries, Ltd.

Treatments:

Fasinumab